The analyst from William Blair highlighted that despite previous challenges, such as the discontinuation of Mersana's former lead program, upifitamab rilsodotin (UpRi), the company's next ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Mersana Therapeutics announced promising Phase ... primarily offset by reduced costs related to clinical development activities for UpRi, a discontinued ADC candidate. General and administrative ...

Mersana Therapeutics ... Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge ...

Date/Time: Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com.

Mersana Therapeutics ... costs related to clinical development activities for our discontinued candidate, UpRi. General and administrative expenses for the fourth quarter of 2024 declined to ...

MERSANA THRPEUTIC ($MRSN) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of -$0.11 per share, beating estimates of -$0.16 by $0 ...

Mersana has continued to advance the dose escalation ... with manufacturing and clinical development activities for UpRi, reduced employee compensation expenses following the company’s ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...